These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 7872320)
1. The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients. Fishbane S; Lynn RI Am J Kidney Dis; 1995 Mar; 25(3):426-32. PubMed ID: 7872320 [TBL] [Abstract][Full Text] [Related]
2. Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic haemodialysis patients. Baldus M; Salopek S; Möller M; Schliesser J; Klooker P; Reddig J; Gansert U; Brass H Nephrol Dial Transplant; 1996 Mar; 11(3):486-91. PubMed ID: 8710158 [TBL] [Abstract][Full Text] [Related]
3. [Red cell zinc protoporphyrin and its ratio to serum ferritin (ZPP/logSF index) in the detection of iron deficiency in patients with end-stage renal failure on hemodialysis]. Matuszkiewicz-Rowińska J; Ostrowski G; Niemczyk S; Przedlacki J; Wardyn K; Puka J; Włodarczyk D; Switalski M; Zakrzewska T; Ostrowski K Pol Arch Med Wewn; 2003 Jul; 110(1):703-10. PubMed ID: 14682204 [TBL] [Abstract][Full Text] [Related]
4. Is zinc protoporphyrin an indicator of iron-deficient erythropoiesis in maintenance haemodialysis patients? Braun J; Hammerschmidt M; Schreiber M; Heidler R; Hörl WH Nephrol Dial Transplant; 1996 Mar; 11(3):492-7. PubMed ID: 8671820 [TBL] [Abstract][Full Text] [Related]
5. Transferrin receptor assay and zinc protoporphyrin as markers of iron-deficient erythropoiesis in end-stage renal disease patients. Baldus M; Walter H; Thies K; Anders C; Stein M; Hellstern P; Brass H Clin Nephrol; 1998 Mar; 49(3):186-92. PubMed ID: 9543601 [TBL] [Abstract][Full Text] [Related]
6. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141 [TBL] [Abstract][Full Text] [Related]
7. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients. Chen YC; Hung SC; Tarng DC Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299 [TBL] [Abstract][Full Text] [Related]
8. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Fishbane S; Lynn RI Clin Nephrol; 1995 Oct; 44(4):238-40. PubMed ID: 8575123 [TBL] [Abstract][Full Text] [Related]
9. Intravenous iron dextran and erythropoietin use in pediatric hemodialysis patients. Greenbaum LA; Pan CG; Caley C; Nelson T; Sheth KJ Pediatr Nephrol; 2000 Sep; 14(10-11):908-11. PubMed ID: 10975297 [TBL] [Abstract][Full Text] [Related]
10. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Tarng DC; Wei YH; Huang TP; Kuo BI; Yang WC Kidney Int; 1999 Jun; 55(6):2477-86. PubMed ID: 10354297 [TBL] [Abstract][Full Text] [Related]
11. Assessment of iron status by erythrocyte ferritin in uremic patients with or without recombinant human erythropoietin therapy. Caravaca F; Vagace JM; Aparicio A; Groiss J; Pizarro JL; Alonso N; Garcia MC; Arrobas M; Cubero J; Esparrago J Am J Kidney Dis; 1992 Sep; 20(3):249-54. PubMed ID: 1519605 [TBL] [Abstract][Full Text] [Related]
12. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Fishbane S; Frei GL; Maesaka J Am J Kidney Dis; 1995 Jul; 26(1):41-6. PubMed ID: 7611266 [TBL] [Abstract][Full Text] [Related]
13. Sensitivity and specificity of transferrin saturation and serum ferritin as markers of iron status after intravenous iron dextran in hemodialysis patients. Low CL; Bailie GR; Eisele G Ren Fail; 1997 Nov; 19(6):781-8. PubMed ID: 9415935 [TBL] [Abstract][Full Text] [Related]
14. [Iron replacement in hemodialysis patients with a normal serum ferritin level]. Riedel MK; Morgenstern T Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155 [TBL] [Abstract][Full Text] [Related]
15. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. Pollak VE; Lorch JA; Shukla R; Satwah S BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700 [TBL] [Abstract][Full Text] [Related]
16. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients. Park L; Uhthoff T; Tierney M; Nadler S Am J Kidney Dis; 1998 May; 31(5):835-40. PubMed ID: 9590194 [TBL] [Abstract][Full Text] [Related]
17. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Markowitz GS; Kahn GA; Feingold RE; Coco M; Lynn RI Clin Nephrol; 1997 Jul; 48(1):34-40. PubMed ID: 9247776 [TBL] [Abstract][Full Text] [Related]
18. A study of parenteral iron regimens in hemodialysis patients. Besarab A; Kaiser JW; Frinak S Am J Kidney Dis; 1999 Jul; 34(1):21-8. PubMed ID: 10401011 [TBL] [Abstract][Full Text] [Related]
19. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy. Tarng DC; Huang TP; Chen TW Am J Nephrol; 1997; 17(2):158-64. PubMed ID: 9096447 [TBL] [Abstract][Full Text] [Related]
20. National perspective on iron therapy as a clinical performance measure for maintenance hemodialysis patients. Owen WF; Szczech L; Johnson C; Frankenfield D Am J Kidney Dis; 1999 Oct; 34(4 Suppl 2):S5-S11. PubMed ID: 10516369 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]